Search Results - S. Lentzsch
- Showing 1 - 20 results of 38
- Go to Next Page
-
1
-
2
-
3
-
4
-
5
Use of daratumumab in high risk multiple myeloma: A meta‐analysis by Vikram Premkumar, Samuel Pan, Suzanne Lentzsch, Divaya Bhutani
Published in eJHaem (2020-07-01)Get full text
Article -
6
-
7
Assessment of Agro-Ecological Apple Replant Disease (ARD) Management Strategies: Organic Fertilisation and Inoculation with Mycorrhizal Fungi and Bacteria by Ulrike Cavael, Peter Lentzsch, Hilmar Schwärzel, Frank Eulenstein, Marion Tauschke, Katharina Diehl
Published in Agronomy (2021-01-01)Get full text
Article -
8
-
9
-
10
-
11
Co-Cultivation of <em>Fusarium</em>, <em>Alternaria</em>, and <em>Pseudomonas</em> on Wheat-Ears Affects Microbial Growth and Mycotoxin Production by Annika Hoffmann, Gunnar Lischeid, Matthias Koch, Peter Lentzsch, Thomas Sommerfeld, Marina E. H. Müller
Published in Microorganisms (2021-02-01)Get full text
Article -
12
Softening of Processed Plant Virus Infected <i>Cucumis sativus</i> L. Fruits by Anne-Katrin Kersten, Sabrina Scharf, Martina Bandte, Peer Martin, Peter Meurer, Peter Lentzsch, Carmen Büttner
Published in Agronomy (2021-07-01)Get full text
Article -
13
Absence of Stat1 in donor CD4+ T cells promotes the expansion of Tregs and reduces graft-versus-host disease in mice by Huihui Ma, Caisheng Lu, Judith Ziegler, Ailing Liu, Antonia Sepulveda, Hideho Okada, Suzanne Lentzsch, Markus Y. Mapara
Published in The Journal of Clinical Investigation (2024-03-01)Get full text
Article -
14
Risk stratification models overestimate progression risk in contemporary patients with smoldering multiple myeloma by George Mellgard, Molly Gilligan, Edward R. Scheffer Cliff, Divaya Bhutani, Ghulam R. Mohyuddin, Andrew Eisenberger, Suzanne Lentzsch, Rajshekhar Chakraborty
Published in HemaSphere (2024-03-01)Get full text
Article -
15
P982: EFFICACY AND SAFETY OF 40 MG VS 60 MG OF ONCE WEEKLY SELINEXOR IN COMBINATION WITH POMALIDOMIDE AND DEXAMETHASONE IN RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM) by Darrell White, Muhamed Baljevic, Gary Schiller, Suzanne Lentzsch, Evgeni Chubar, Noa Lavi, Dane Van Domelen, Ohad Bentur, Sumit Madan
Published in HemaSphere (2023-08-01)Get full text
Article -
16
Long-term follow-up of patients with AL amyloidosis treated on a phase 1 trial of CAEL-101 by Michael Sang Hughes, Samuel Pan, Rajshekhar Chakraborty, Jayant Raikhelkar, Mathew S. Maurer, Markus Y. Mapara, Andrew Eisenberger, Suzanne Lentzsch, Divaya Bhutani
Published in Blood Advances (2025-10-01)Get full text
Article -
17
IMiD compounds affect CD34+ cell fate and maturation via CRBN-induced IKZF1 degradation by Shirong Li, Jing Fu, Hui Wang, Huihui Ma, Xiaoming Xu, Yong-Guang Yang, Shixian Deng, Markus Y. Mapara, Suzanne Lentzsch
Published in Blood Advances (2018-03-01)Get full text
Article -
18
Efficacy and safety of once weekly selinexor 40 mg versus 60 mg with pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma by Darrell White, Gary J. Schiller, Sumit Madan, Suzanne Lentzsch, Evgeni Chubar, Noa Lavi, Dane R. Van Domelen, Ohad S. Bentur, Muhamed Baljevic
Published in Frontiers in Oncology (2024-05-01)Get full text
Article -
19
The checkpoint inhibitor PD-1H/VISTA controls osteoclast-mediated multiple myeloma bone disease by Jing Fu, Shirong Li, Huihui Ma, Jun Yang, Gabriel M. Pagnotti, Lewis M. Brown, Stephen J. Weiss, Markus Y. Mapara, Suzanne Lentzsch
Published in Nature Communications (2023-07-01)Get full text
Article -
20
GCK inhibition enhances iberdomide antimyeloma effects by promoting IKZF1 degradation via a CRBN-independent mechanism by Shirong Li, Josefine Krüger, Guifen Liu, Huihui Ma, Michael S. Hughes, Rajshekhar Chakraborty, Divaya Bhutani, Markus Y. Mapara, Christophe Marcireau, Suzanne Lentzsch, Jing Fu
Published in Blood Neoplasia (2025-08-01)Get full text
Article
